Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke

European Journal of Clinical Investigation

Volumn 45, Issue 6, 2015, Pages 579-586

  Carbone, Federico ^a,b   Vuilleumier, Nicolas ^c   Burger, Fabienne ^b   Roversi, Gloria ^d   Tamborino, Carmine ^d   Casetta, Ilaria ^d   Seraceni, Silva ^d   Trentini, Alessandro ^d   Padroni, Marina ^d   Dallegri, Franco ^a   Mach, François ^b   Fainardi, Enrico ^d   Montecucco, Fabrizio ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Ischaemic stroke; Osteopontin; Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; BIOLOGICAL MARKER; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; BLOOD SAMPLING; BRAIN ISCHEMIA; CLINICAL EXAMINATION; COHORT ANALYSIS; COLORIMETRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RANKIN SCALE; RECEIVER OPERATING CHARACTERISTIC; UPREGULATION; BLOOD; CEREBROVASCULAR ACCIDENT; DISABLED PERSON; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

AGED; BIOMARKERS; BRAIN ISCHEMIA; DISABLED PERSONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; OSTEOPROTEGERIN; PROGNOSIS; PROSPECTIVE STUDIES; RANK LIGAND; STROKE; UP-REGULATION;

EID: 84929512076     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12446     Document Type: Article

References (42)

1. McKee MD, Pedraza CE, Kaartinen MT. Osteopontin and wound healing in bone. Cells Tissues Organs 2011;194:313-9.
2. Trouvin AP, Goëb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010;5:345-54.
3. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007;2007:75805.
4. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:2302-9.
5. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal 2009;3:311-22.
6. Boyce BF, Rosenberg E, de Papp AE, Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012;42:1332-41.
7. Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 2007;179:7497-505.
8. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80.
9. Lenglet S, Quercioli A, Fabre M, Galan K, Pelli G, Nencioni A et al. Statin treatment is associated with reduction in serum levels of receptor activator of NF-kappaB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm 2014;2014:720987.
10. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010;267:410-7.
11. Song TJ, Kim J, Yang SH, Park JH, Lee HS, Nam CM et al. Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers 2012;17:738-44.
12. Mendioroz M, Fernández-Cadenas I, Rosell A, Delgado P, Domingues-Montanari S, Ribó M et al. Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol 2011;258:486-93.
13. Meller R, Stevens SL, Minami M, Cameron JA, King S, Rosenzweig H et al. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 2005;25:217-25.
14. Chen W, Ma Q, Suzuki H, Hartman R, Tang J, Zhang JH. Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model. Stroke 2011;42:764-9.
15. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:2064-89.
16. Carbone F, Vuilleumier N, Bertolotto M, Burger F, Galan K, Roversi G et al. Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. Vascul Pharmacol 2015; 64: 16-27.
17. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711.
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
19. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-70.
20. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
21. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670-4.
22. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009;11:206-13.
23. Quercioli A, Montecucco F, Bertolotto M, Ottonello L, Pende A, Mach F et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. Eur J Clin Invest 2010;40:645-54.
24. Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 2012;46:203-11.
25. Wang X, Louden C, Yue TL, Ellison JA, Barone FC, Solleveld HA et al. Delayed expression of osteopontin after focal stroke in the rat. J Neurosci 1998;18:2075-83.
26. Suezawa C, Kusachi S, Murakami T, Toeda K, Hirohata S, Nakamura K et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med 2005;145:33-40.
27. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994;145:1450-62.
28. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515-24.
29. Shin YJ, Kim HL, Choi JS, Choi JY, Cha JH, Lee MY. Osteopontin: correlation with phagocytosis by brain macrophages in a rat model of stroke. Glia 2011;59:413-23.
30. Momiyama Y, Ohmori R, Fayad ZA, Kihara T, Tanaka N, Kato R et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 2010;210:668-70.
31. Mazzone A, Parri MS, Giannessi D, Ravani M, Vaghetti M, Altieri P et al. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coron Artery Dis 2011;22:179-87.
32. Bjerre M, Pedersen SH, Møgelvang R, Lindberg S, Jensen JS, Galatius S et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol 2013;20:922-9.
33. Mazière C, Gomila C, Mazière JC. Oxidized low-density lipoprotein increases osteopontin expression by generation of oxidative stress. Free Radic Biol Med 2010;48:1382-7.
34. Jiménez-Corona AE, Damián-Zamacona S, Pérez-Torres A, Moreno A, Mas-Oliva J. Osteopontin upregulation in atherogenesis is associated with cellular oxidative stress triggered by the activation of scavenger receptors. Arch Med Res 2012;43:102-11.
35. Bishop E, Theophilus EH, Fearon IM. In vitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers. BMC Cardiovasc Disord 2012;12:75.
36. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-96.
37. Iwanaga Y, Ueno M, Ueki M, Huang CL, Tomita S, Okamoto Y et al. The expression of osteopontin is increased in vessels with blood-brain barrier impairment. Neuropathol Appl Neurobiol 2008;34:145-54.
38. Pantano P, Caramia F, Bozzao L, Dieler C, von Kummer R. Delayed increase in infarct volume after cerebral ischemia: correlations with thrombolytic treatment and clinical outcome. Stroke 1999;30:502-7.
39. Fitzek S, Fitzek C, Urban PP, Marx J, Hopf HC, Stoeter P. Time course of lesion development in patients with acute brain stem infarction and correlation with NIHSS score. Eur J Radiol 2001;39:180-5.
40. Vik A, Mathiesen EB, Johnsen SH, Brox J, Wilsgaard T, Njølstad I et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population-the Tromsø study. J Thromb Haemost 2010;8:898-905.
41. Giaginis C, Papadopouli A, Zira A, Katsargyris A, Klonaris C, Theocharis S. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor kappaB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 2012;18:CR597-604.
42. Üstündağ M, Orak M, Güloğlu C, Tamam Y, Sayhan MB, Kale E. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res 2011;39:780-9.